Phase II study of S-1 plus oxaliplatin (130 mg/m2, every 3 weeks) for advanced gastric cancer
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 21 Jan 2017 Status changed from active, no longer recruiting to completed.
- 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium
- 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.